



**DISK TO STIC**

DATE: \_\_\_\_\_



**BEST AVAILABLE COPY**



LAW OFFICES OF  
**SYNNESTVEDT & LECHNER LLP**

2600 ARAMARK TOWER  
1101 MARKET STREET  
PHILADELPHIA, PA 19107-2950  
TELEPHONE (215) 923-4466

**RECEIVED**

APR 1 2 2002

FACSIMILE (215) 923-2189  
E-MAIL [synnleach@synnleach.com](mailto:synnleach@synnleach.com)  
[www.synnleach.com](http://www.synnleach.com)

TECH CENTER 1600/2900 March 28, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of M. Jaye, K. Doan, J. Krawiec, K. Lynch, D. Amin, V. South,  
D. Marchadier, C. Maugeais, and D. Rader

Application No. 09/277,401

Group No. 1652

Filed December 5, 1997


Examiner D. Ramirez

Compositions and Methods for Effecting the Levels of High Density Lipoprotein  
(HDL) Cholesterol and Apolipoprotein AI, Very Low Density Lipoprotein  
(VLDL) Cholesterol and Low Density Lipoprotein (LDL) Cholesterol

(Atty. Docket No. P 22,944-C USA)

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231, on Thursday, March 28, 2002.

  
Jaclyn M. Schlitter

Commissioner for Patents  
Washington, D.C. 20231

AMENDMENT UNDER 37 CFR §1.825 AND  
SUBMISSION OF SEQUENCE LISTING UNDER 37 CFR §1.821

Sir:

Applicants submit herewith a paper copy and a computer-readable copy of a

1652  
#1317  
04/16/02

Group No. 1652  
Application No. 09/277,401

March 28, 2002  
Attorney Docket No. P 22,944-C USA  
Page 2

revised Sequence Listing which corrects clerical errors made in a Sequence Listing that was filed concurrently with the present application. An explanation of the amendments which are included in the revised Sequence Listing is set forth hereafter.

SEQ ID NO: 13, which represents the amino acid sequence of lipoprotein lipase (LPL), has been amended to correctly include a leucine residue at position 130, a serine residue at position 196, and a valine residue at position 264. The correct sequence for lipoprotein lipase is shown in the application at Figure 6.

SEQ ID NOS: 3, 5, 7, 9, and 11, as originally filed, included erroneous numbering in which the numbering of the amino acid sequences did not start at 1. This has been corrected by the present amendment.

SEQ ID NOS: 1, 2, 5, 6, 7, and 8, as originally filed, included the use of an asterisk (\*) to represent the end of an amino acid sequence. With the present amendment, the asterisk has been removed to place the sequences in conformity with Patent Office practice.

No new matter has been added by the present amendment. Accordingly, entry of the present amendment is requested under 37 CFR §1.312.

CERTIFICATION UNDER 37 CFR §1.821

Pursuant to 37 CFR §1.821, it is certified hereby that the content of the paper copy of the Sequence Listing is identical to that of the computer readable copy of

Group No. 1652  
Application No. 09/277,401

March 28, 2002  
Attorney Docket No. P 22,944-C USA  
Page 3

the same Sequence Listing submitted herewith.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Gene J. Yao', is written over a horizontal line.

Gene J. Yao, Esquire  
Reg. No. 47,193  
Attorney for Applicants

Synnestvedt & Lechner LLP  
Suite 2600 Aramark Tower  
1101 Market Street  
Philadelphia, PA 19107-2950  
(215) 923-4466

GJY/jms

M:\GYao\22,944-C USA\PTO Correspondence\Submission of Sequence Listing.2.wpd